U.S. markets closed

Veracyte, Inc. (VCYT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
26.03-0.03 (-0.12%)
At close: 04:00PM EST
27.33 +1.30 (+4.99%)
After hours: 07:03PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close26.06
Bid24.37 x 1000
Ask27.59 x 800
Day's Range25.61 - 26.34
52 Week Range14.85 - 33.23
Avg. Volume923,909
Market Cap1.868B
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)-0.69
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VCYT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Veracyte, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/14/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    8 months agoArgus Research
View more
  • Motley Fool

    Better Long-Term Buy in 2023: Exact Sciences or Veracyte?

    Veracyte (NASDAQ: VCYT) and Exact Sciences (NASDAQ: EXAS) focus on genomic tests to diagnose various cancers. A report by BIS Research puts the molecular cancer diagnostics market at $4.1 billion in 2022 but with a compound annual growth rate (CAGR) of 11.4% through 2032, reaching a $12.1 billion market by that time. Cancer is formed by changes to the genome in a body's cells, leading to uncontrollable growth.

  • GlobeNewswire

    Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors

    SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has served as Chair of the Board of Directors at Exagen since 2018, and who will remain a member of the Board. Dr. Nova currently serves as President of Veracyte's (Nasdaq: VCYT) U.S. CLIA business where

  • Motley Fool

    This Small-Cap Stock Is a No-Brainer Buy

    This genomic test maker's stock was beaten down in 2022. But it could be heading for a rebound this year.